A number of other equities research analysts have also commented on GNS. Liberum Capital restated a hold rating on shares of Genus in a report on Wednesday, June 27th. Kepler Capital Markets raised their price objective on shares of Genus from GBX 2,353 ($30.35) to GBX 2,470 ($31.86) and gave the stock a hold rating in a report on Wednesday, July 4th. Five investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The stock currently has an average rating of Hold and an average target price of GBX 2,273.33 ($29.33).
Shares of LON:GNS traded down GBX 98 ($1.26) during midday trading on Thursday, reaching GBX 2,444 ($31.53). 156,484 shares of the company were exchanged, compared to its average volume of 78,154. Genus has a fifty-two week low of GBX 1,652 ($21.31) and a fifty-two week high of GBX 2,597 ($33.50).
The business also recently disclosed a dividend, which will be paid on Friday, November 30th. Investors of record on Thursday, November 15th will be issued a dividend of GBX 17.90 ($0.23) per share. This represents a dividend yield of 0.7%. This is a positive change from Genus’s previous dividend of $8.10. The ex-dividend date of this dividend is Thursday, November 15th.
In other Genus news, insider Lesley Knox bought 2,000 shares of the firm’s stock in a transaction that occurred on Monday, June 11th. The stock was acquired at an average price of GBX 2,670 ($34.44) per share, with a total value of £53,400 ($68,885.45).
Genus plc, together with its subsidiaries, engages in the application of quantitative genetics and biotechnology for animal breeding in the porcine and bovine sectors. It operates through three segments: Genus PIC, Genus ABS, and Research and Development. The company sells sows, boars, and semen under the PIC name to breed pigs with various characteristics for pork production.
Recommended Story: Asset Allocation Models, Which is Right For You?
Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.